These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33838847)

  • 21. Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Hatziantoniou S; Maltezou HC; Tsakris A; Poland GA; Anastassopoulou C
    Vaccine; 2021 May; 39(19):2605-2607. PubMed ID: 33846043
    [No Abstract]   [Full Text] [Related]  

  • 22. How important is the second dose of the COVID-19 mRNA vaccine?
    Liu AY
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2537. PubMed ID: 34112480
    [No Abstract]   [Full Text] [Related]  

  • 23. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 25. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
    Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
    [No Abstract]   [Full Text] [Related]  

  • 26. [Not Available].
    Klimek L; Chaker AM; Cuevas M
    Laryngorhinootologie; 2021 May; 100(5):344-354. PubMed ID: 33684947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 28. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase.
    Koo G; Anvari S; Friedman DL; Zarnegar-Lumley S; Szafron V; Kahwash BM; Onasch KM; Hall L; Phillips EJ; Stone CA
    J Allergy Clin Immunol Pract; 2022 Jan; 10(1):322-325. PubMed ID: 34678498
    [No Abstract]   [Full Text] [Related]  

  • 31. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID-19 Response, Medicaid, And More.
    Weil AR
    Health Aff (Millwood); 2021 Jan; 40(1):7. PubMed ID: 33400575
    [No Abstract]   [Full Text] [Related]  

  • 33. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 35. Vaccines against COVID-19.
    Locht C
    Anaesth Crit Care Pain Med; 2020 Dec; 39(6):703-705. PubMed ID: 33096260
    [No Abstract]   [Full Text] [Related]  

  • 36. An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history.
    Krantz MS; Stone CA; Rolando LA; Nobis AE; Koo G; Corey KB; Bluestein SB; Staso PJ; Campbell EM; Phillips EJ
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3807-3810. PubMed ID: 34293499
    [No Abstract]   [Full Text] [Related]  

  • 37. Current advances in the development of SARS-CoV-2 vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Status of Diagnostic Testing for SARS-CoV-2 Infection and Future Developments: A Review.
    Gao J; Quan L
    Med Sci Monit; 2020 Dec; 26():e928552. PubMed ID: 33332288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19.
    Vollmann D; Eiffert H; Schuster A
    Dtsch Arztebl Int; 2021 Aug; 118(31-32):546. PubMed ID: 34515024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.